Medscape
The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The subcutaneous (SC) injection can be administered by a healthcare professional in approximately 10 minutes and is the first and only …
Read More
FDA Okays Subcutaneous Ocrelizumab for MS
Randy Volkman
17:47
The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The subcutaneous (SC) injection can be administered by a healthcare professional in approximately 10 minutes and is the first and only
